Developing a self-management package for pulmonary fibrosis: an international Delphi study

Author:

Lee Joanna Y.T.ORCID,Tikellis Gabriella,Khor Yet H.ORCID,Holland Anne E.ORCID

Abstract

RationaleSelf-management is considered as an important part of disease management for people with pulmonary fibrosis (PF), but there is a lack of consensus regarding what components should be included. This study aimed to attain consensus from experts in PF and people living with the disease on the essential components and format of a PF self-management package.MethodsA two-round Delphi process was conducted. In each round, a panel of experts completed an online survey to rate a range of components, formats and delivery methods, followed by an online patient focus group to integrate patient perspectives. Consensus was defineda priori.Results45 experts participated in Round 1 and 51 in Round 2. Both focus groups included six people with PF. 12 components were considered essential for self-management in PF: 1) understanding treatment options; 2) understanding and accessing clinical trials; 3) managing medications; 4) role of oxygen therapy; 5) role and importance of pulmonary rehabilitation and regular physical activity; 6) managing shortness of breath; 7) managing fatigue; 8) managing mood; 9) managing comorbidities; 10) smoking cessation advice and support; 11) accessing community support; and 12) how to communicate with others when living with PF. Both groups agreed that self-management in PF required individualisation, goal setting and feedback.ConclusionThis study identified 12 essential components and highlighted individualisation, goal setting and feedback in self-management of PF. The findings provide a basis for the development of PF self-management interventions.

Publisher

European Respiratory Society (ERS)

Subject

Pulmonary and Respiratory Medicine

Reference43 articles.

1. An Official American Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias

2. Fibrosing interstitial lung diseases: knowns and unknowns

3. Australian Government Department of Health Therapeutic Goods Administration . Australian public assessment report for pirfenidone. https://www.tga.gov.au/sites/default/files/auspar-pirfenidone-160809.pdf Date last updated: 9 August 2016. Date last accessed: 6 July 2022.

4. U.S. Food and Drug Administration . New drug therapy approvals 2020: advancing health through innovation. https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/new-drug-therapy-approvals-2020 Date last updated: 1 August 2021. Date last accessed: 6 July 2022.

5. Australian Government Department of Health Therapeutic Goods Administration . Australian public assessment report for nintedanib (as Esilate). https://www.tga.gov.au/sites/default/files/auspar-nintedanib-as-esilate-210226.pdf Date last updated: 26 February 2021. Date last accessed: 6 July 2022.

Cited by 9 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3